-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A covid-19 pandemic that has swept the world has not only completely changed the existing way humans live and behave, but also pushed mRNA technology, which has been unsatisfactory for many years, to the cusp
Recently, eTheRNA, a Belgian-based company specializing in mRNA technology, raised up to 39 million euros in the B2 round of financing, which attracted major media coverage
At the same time as this round of investment, the addition of two new investors has greatly attracted the attention of many followers: Dr.
Because Moderna is facing a patent infringement lawsuit with Arbutus Biopharma, involving six U.
Although the application of mRNA drugs and therapeutic vaccines in the field of tumor treatment is still in the proof-of-concept stage, it is necessary to overcome key technical bottlenecks such as off-target effects and expression instability, bioNTech and Modernna, pioneer enterprises of mRNA drugs, have corresponding pipelines to enter the clinical stage, and the market size is also growing year by year, which shows its future development potential
Founded in 2013, eTheRNA already has a full suite of proven integrated pipelines for designing, developing and manufacturing end-to-end solutions for next-generation mRNA products
The mRNA track of foreign biopharmaceutical companies is in full swing, and major domestic pharmaceutical companies are not far behind
Just half a year later, Broad Pharma and eTheRNA further deepened their cooperation and invested 8.
Auror Bio landed in the Biomedical Valley of Jiangbei New Area, Nanjing, and is expected to complete the technology transfer of LNP preparations in 2022, and initially build a complete research and development platform, and the "Gene City" of the pilot free trade zone is also highly expected
In addition, founded in 2016, Si Microbial has completed a round of financing of 30 million yuan, and received a strategic investment of 351 million yuan from Tibet Pharmaceutical last year, with a strong mRNA synthesis and lipid polymer nanocarrier technology platform (LPP
Si Microbial Abbott Bio Blue Magpie Bio, Minor Hengkang, Deep Belief Bio, Levanda Bio, Thick Storage Nano, St.
If the new crown epidemic has introduced mRNA technology into the public eye like a catalyst, and achieved a breakthrough of "0" to "1" in the past six decades, then the major mRNA biotechnology companies that have sprung up will push "1" to infinity, which is expected to usher in a market size of 100 billion, and rewrite the history
